Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | NFKBIA | P25963 | 3/20 | 0.55 |
| ▸ | RELA | Q04206 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.54 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.54 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3948004 | 0.77 | ALDH1A1 (0.56) | SMN1; SMN2GAANFKBIARELAMEN1 | |
| SCHEMBL17805683 | 0.77 | PKM (0.71) | SMN1; SMN2GAAPKMNFKBIARELA | |
| SCHEMBL26844388 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2GAAPKMNFKBIARELA | |
| SCHEMBL7451030 | 0.76 | PKM (0.64) | SMN1; SMN2GAAPKMNFKBIARELA | |
| SCHEMBL31275770 | 0.74 | KMT2A (0.54) | SMN1; SMN2GAAPKMNFKBIARELA | |
| SCHEMBL29134055 | 0.74 | KMT2A (0.67) | SMN1; SMN2GAAMEN1KMT2ALMNA | |
| SCHEMBL3780817 | 0.74 | PKM (0.63) | SMN1; SMN2GAAPKMNFKBIARELA | |
| SCHEMBL31421803 | 0.74 | PKM (0.67) | SMN1; SMN2GAAPKMNFKBIARELA | |
| SCHEMBL11973619 | 0.74 | SLC40A1 (0.68) | SMN1; SMN2GAAPKMNFKBIARELA | |
| SCHEMBL4291285 | 0.74 | ALDH1A1 (0.68) | SMN1; SMN2GAAPKMNFKBIARELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511043-B2 | FXR modulators | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511043-B2 | FXR modulators | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511043-B2 | FXR modulators | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20040176426-A1 | FXR modulators | TULARIK, INC. | 2004-09-09 | — | — | US | disclosed |
| US-6777446-B2 | FARNESOID X RECEPTOR; TREATING DISEASES ASSOCIATED WITH ABNORMALLY HIGH OR LOW CHOLESTEROL LEVELS. | TULARIK, INC. | 2004-08-17 | — | — | US | disclosed |
| US-20020120137-A1 | Farnesoid X receptor; treating diseases associated with abnormally high or low cholesterol levels. | TULARIK INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002020463-A2 | FXR MODULATORS | TULARIK INC. (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120137-A1 | Farnesoid X receptor; treating diseases associated with abnormally high or low cholesterol levels. | NR1H4, NR1H2, NR1H3 | SMN1; SMN2 4857/4885GAA 1648/4885PKM 4032/4885 |
| US-20040176426-A1 | FXR modulators | NR1H4, CYP7A1, CYP7B1 | SMN1; SMN2 4872/4885GAA 1092/4885PKM 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.